| Aestis is currently raising $1.25 million in
seed financing to fund preclinical trials. The trials will be a blinded
study with c.a. 30 subjects and 30 controls with a hypoxic exposure
period of 3-4 weeks. $300,000 will be used for equipment, $700,000 for
site study costs and $250,000 for the company’s study costs, including
consultant fees. These studies are expected to be completed in nine
months. Series A financing will be raised upon completion of the
preclinical trials. Qualified investors are invited to review the
company’s business plan. |
|
|
